Cure CMD Research Grant Goals
Cure CMD research goals reflect our mission to bring research, treatments and in the future, a cure for the congenital muscular dystrophies.
- Identify new therapeutic targets in the CMDs
- Identify small molecule compounds that work at these therapeutic target sites with priority towards drugs with existing pediatric FDA approval
- Facilitate the drug development process to ensure that each positive drug identification with promising preliminary data can be brought rapidly to preclinical trials and subsequent treatment trials
- Support and endorse clinical research, infrastructure and biomarker discovery required to launch effective and efficient clinical trials in rare disease
- Advance drug discovery with a diverse treatment pipeline
- Support new scientific investigators with innovative ideas and a commitment to CMD research
Grant Application – Deadline September 15, 2013!
Cure CMD General Research Grants: Annual Deadline Sept 15th
submit to: email@example.com
Cure CMD Short Term Research Grant: Cure CMD provides a short-range or “seed” grant (usually $30,000 per year for 1-2 years, direct costs only) to attract new investigators to the CMD field and assist existing investigators to support early phases of their research. The short-range grant focus is to collect preliminary data and test initial hypotheses. The short-range grant goal is to translate successful preliminary research to either second tier Cure CMD midrange grants (R-21 type) or third tier, long range (R-01 grants, 2-5 years) from outside funding sources, such as the National Institutes of Health. Annual RFA deadline, Sept 15th. Grant application above. On the first page of the Cure CMD grant application, specify CMD Short Term CMD Research Grant.
Cure CMD Midrange grant: Cure CMD provides a 1-2 year midrange grant targeting more mature research, (usually $50,000 per year for 1-2 years, direct costs only). This grant submission requires evidence of preliminary data supporting hypothesis driven research. Funding support for these two tiered research grants comes from Cure CMD. Grant application above. On the first page of the Cure CMD grant application, specify Midrange Grant.
2011 Cure CMD Grant Recipients:
- Dr. Gisele Bonne, PhD, INSERM, France, “Novel Trans-splicing Mechanism for LMNA related dystrophy”
- Dr. James Dowling, MD, PhD, University of Michigan, “Zebrafish Models of CMD”
- Dr. William Cruikshank, PhD, Boston University, “Evaluating the Respiratory System in a CMD Animal Model (Dyw)”
2010 Cure CMD Short Term Research Grant Recipients:
- Dr. Susan Brown, Royal Veterinary College, United Kingdom, “Validation of an Animal Model for Therapeutic Testing In the Dystroglycanopathies” (2 year funding)
- Dr. Kanneboyina Nagaraju, CNMC, USA, “Validation of Omigapil in LAMA2 Related CMD Animal Model and Endpoint Validation in Col6KI Model” (supplemental funding to CTSA)
2010 Cure CMD Midrange Research Grant Recipients:
- Dr. Valerie Allamand, INSERM, Institute de Myologie, France, “PTC Suppression in a Novel Model of Col6 Myopathy” (2 year funding)
- Drs. Olga Igoucheva and Mon-li Chu, Thomas Jefferson University, USA, “Therapeutic Potential of Adult Stem Cells for Collagen 6 Muscular Dystrophy” (2 year funding)
2010 SAM CMD Translational Research Grant Recipient:
- Dr. Sweta Girgenrath, Boston University, USA, “To Evaluate the Efficacy of RAP-031 Treatment of Dystrophic, Inflammatory and Regenerative Deficiencies in Merosin Deficient Congenital Muscular Dystrophy Animal Model” (1 year funding)
2009 Cure CMD Short Term Research Grant Recipient:
- Dr. Ana Ferreiro, INSERM, France, “Pharmacological Therapy of SEPN1 Related Myopathy: From Ex Vivo Studies to the First Clinical Trial” (1 year funding)
2009 SAM CMD Translational Award Recipients:
- Dr. Denis Guttridge, Ohio State University Medical Center, “Elucidating NF-kappa B Function in Congenital Muscular Dystrophy” (2 year funding)
- Dr. Sweta Girgenrath, Boston University, USA, “Triggering Regeneration and Tackling Degeneration: A Comprehensive Approach for Treating Muscular Dystrophy”
- Dr. James Collins, Cincinnati Childrens Hospital Medical Center, USA, “Transciptomic and Proteomic Profiling in Blood of Patients with Laminin Alpha 2 Deficiency; A Biomarker Pilot Study” (1 year funding)
- Dr. Dean Burkin, University of Nevada, USA, “Laminin 111 Protein Therapy for Merosin Deficient Congenital Muscular Dystrophy” (1 year funding)